- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00147719
WelChol® With Metformin in Treating Patients With Type 2 Diabetes
January 16, 2012 updated by: Daiichi Sankyo, Inc.
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Monotherapy or Metformin Therapy in Combination With Other Oral Anti-Diabetic Agents
The purpose of the study is to see how safe and effective and tolerable the use of colesevelam hydrochloride is for type 2 diabetes when added to metformin alone or in combination with other anti-diabetic drugs.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
300
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Mexico DF, Mexico
-
-
-
-
-
Lima, Peru
-
-
-
-
Arkansas
-
Jonesboro, Arkansas, United States
- cro
-
-
California
-
Beverly Hills, California, United States
-
Carmichael, California, United States
-
Fresno, California, United States
-
Irvine, California, United States
-
La Jolla, California, United States
-
Los Gatos, California, United States
-
San Diego, California, United States
-
Spring Valley, California, United States
-
West Hills, California, United States
-
-
District of Columbia
-
Washington, District of Columbia, United States
-
-
Florida
-
Coco Beach, Florida, United States
-
Largo, Florida, United States
-
Miami, Florida, United States
-
Pembroke Pines, Florida, United States
-
West Palm Beach, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States
-
-
Indiana
-
Evansville, Indiana, United States
-
-
Kentucky
-
Louisville, Kentucky, United States
-
-
Michigan
-
Detroit, Michigan, United States
-
Troy, Michigan, United States
-
-
Minnesota
-
Edina, Minnesota, United States
-
-
Missouri
-
Chesterfield, Missouri, United States
-
-
Montana
-
Bozeman, Montana, United States
-
Butte, Montana, United States
-
-
Nevada
-
Las Vegas, Nevada, United States
-
-
New York
-
Rochester, New York, United States
-
-
North Carolina
-
Charlotte, North Carolina, United States
-
Winston-Salem, North Carolina, United States
-
-
Ohio
-
Cincinnati, Ohio, United States
-
Cleveland, Ohio, United States
-
Lyndhurst, Ohio, United States
-
Marion, Ohio, United States
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
-
Tulsa, Oklahoma, United States
-
-
Oregon
-
Portland, Oregon, United States
-
-
Pennsylvania
-
Beaver, Pennsylvania, United States
-
-
South Carolina
-
Charleston, South Carolina, United States
-
Columbia, South Carolina, United States
-
-
Tennessee
-
Morristown, Tennessee, United States
-
-
Texas
-
Corpus Christi, Texas, United States
-
Dallas, Texas, United States
-
Pharr, Texas, United States
-
San Antonio, Texas, United States
-
-
Virginia
-
Arlington, Virginia, United States
-
Richmond, Virginia, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18-75 years, inclusive
- Diagnosed with type 2 diabetes
- Hemoglobin (HbA1c) between 7.5% to 9.5%
- Prescribed an ADA accepted diet
- Receiving stable dose of metformin alone or in combination with other oral anti-diabetic medications for 90 days before Visit 1
Exclusion Criteria:
- History of type 1 diabetes or ketoacidosis
- History of chronic (more than 2 months) insulin therapy or the initiation of insulin for chronic treatment
- History of pancreatitis
- Uncontrolled hypertension
- Recent severe cardiovascular disease
- Allergy or toxic response to colesevelam or any of its components
- Body mass index (BMI) >45 kg/m2
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
To assess the additional lowering of HbA1C achieved by addition of colesevelam hydrochloride to current antidiabetic therapy
|
Secondary Outcome Measures
Outcome Measure |
---|
To assess the fasting plasma glucose and fructosamine lowering effect;
|
To assess the glycemic control response rate;
|
To assess the improvement in insulin sensitivity;
|
To assess the effect on high sensitivity C-reactive protein;
|
To assess the improvement in lipids, and lipoproteins;
|
To assess the safety and tolerability of colesevelam hydrochloride when added on to current therapy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2004
Primary Completion (Actual)
July 1, 2006
Study Completion (Actual)
July 1, 2006
Study Registration Dates
First Submitted
September 2, 2005
First Submitted That Met QC Criteria
September 2, 2005
First Posted (Estimate)
September 7, 2005
Study Record Updates
Last Update Posted (Estimate)
January 18, 2012
Last Update Submitted That Met QC Criteria
January 16, 2012
Last Verified
January 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- WEL-301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Colesevelam hydrochloride
-
University of Colorado, DenverDaiichi Sankyo, Inc.CompletedDiabetes Mellitus, Type 1 | HyperlipidemiasUnited States
-
Daiichi Sankyo, Inc.CompletedType 2 DiabetesUnited States, Peru, Mexico
-
Daiichi Sankyo, Inc.CompletedType 2 DiabetesUnited States, Peru, Mexico
-
Seattle Institute for Biomedical and Clinical ResearchVA Puget Sound Health Care SystemCompletedPrediabetes | Impaired Fasting Glucose
-
Daiichi Sankyo, Inc.CompletedType 2 Diabetes Mellitus | Hypercholesterolemia | Pre-diabetesUnited States, Colombia, India, Mexico
-
Daiichi Sankyo, Inc.CompletedType 2 Diabetes MellitusUnited States
-
Daiichi Sankyo, Inc.CompletedType 2 DiabetesUnited States, Peru, Mexico
-
Genzyme, a Sanofi CompanyCompletedFamilial HypercholesterolemiaNetherlands, France, Germany, Sweden, United Kingdom
-
Foundation for Liver ResearchCompleted
-
Daiichi Sankyo, Inc.Completed